Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery by Engsig, Frederik N. et al.
H I V / A I D S M A J O R A R T I C L E
Long-term Mortality in HIV-Positive Individuals
Virally Suppressed for >3 Years With Incomplete
CD4 Recovery
Frederik N. Engsig,1,2 Robert Zangerle,3 Olga Katsarou,4 Francois Dabis,5 Peter Reiss,6,7 John Gill,8 Kholoud Porter,9
Caroline Sabin,10 Andrew Riordan,11 Gerd Fätkenheuer,12 Félix Gutiérrez,13 Francois Rafﬁ,14 Ole Kirk,1,15
Murielle Mary-Krause,16 Christoph Stephan,17 Patricia Garcia de Olalla,18 Jodie Guest,19 Hasina Samji,20
Antonella Castagna,21 Antonella d’Arminio Monforte,22 Adriane Skaletz-Rorowski,23 Jose Ramos,24 Giuseppe Lapadula,25
Cristina Mussini,26 Lluís Force,27 Laurence Meyer,28 Fiona Lampe,29 Faroudy Boufassa,30 Heiner C. Bucher,31
Stéphane De Wit,32 Greer A. Burkholder,33 Ramon Teira,34 Amy C. Justice,35,36 Tim R. Sterling,37 Heidi M. Crane,38
Jan Gerstoft,1 Jesper Grarup,15 Margaret May,39 Geneviève Chêne,5 Suzanne M. Ingle,39 Jonathan Sterne,39 and
Niels Obel1; for the Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV
Epidemiological Research Europe (COHERE) in EuroCoord
1Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, and 2Department of Microbiological Diagnostics and Virology,
Statens Serum Institut, Copenhagen, Denmark; 3Department of Dermatology and Venerology, Innsbruck Medical University, Austria; 4Blood Centre and
National Reference Centre for Congenital Bleeding Disorders, Laiko General Hospital, Athens, Greece; 5University Bordeaux, ISPED, Centre Inserm U897-
Epidemiologie-Biostatistique, Bordeaux, France; 6Academic Medical Center, Department of Global Health, Amsterdam; 7Stichting HIV Monitoring,
Amsterdam, The Netherlands; 8Department of Medicine, University of Calgary, Alberta, Canada; 9MRC Clinical Trials Unit, London, and 10Research
Department of Infection and Population Health, University College London, and 11Department of Paediatric Infectious Diseases and Immunology, Alder Hey
Children’s NHS Foundation Trust, Liverpool, United Kingdom; 12First Department of Internal Medicine, University of Cologne, Germany; 13Infectious
Diseases Unit, Hospital General Universitario de Elche, Universidad Miguel Hernández, Alicante, Spain; 14Infectious Diseases Department and HIV Clinical
Research Unit, Hotel Dieu University Hospital, Nantes, France; 15Copenhagen HIV Programme, Panum Institute, University of Copenhagen, Denmark;
16L’Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche en Santé 943, University Pierre and Marie Curie,
Hospital Pitie-Salpetriere, Paris, France; 17Department of Infectious Disease, Goethe University Hospital, Frankfurt/Main, Germany; 18Epidemiology
Service, Public Health Agency of Barcelona, Spain; 19Atlanta Veterans Affairs Medical Center, Georgia; 20British Columbia Centre for Excellence in HIV/
AIDS, Vancouver, Canada; 21Department of Infectious and Tropical Diseases, San Raffaele Scientiﬁc Institute, and 22Infectious Diseases Unit, Department
of Health Sciences, San Paolo University Hospital, Milan, Italy; 23Competence Network for HIV/AIDS, Ruhr-Universität Bochum, Germany; 24Pediatrics
Department, Hospital Universitario de Getafe, Madrid, Spain; 25Division of Infectious Diseases, Department of Internal Medicine, “San Gerardo” Hospital,
University of Milan-Bicocca, Monza, and 26Clinic of Infectious Diseases, Department of Internal Medicine, Medical Specialties University of Modena and
Reggio Emilia, Italy; 27Infectious Diseases Unit, Hospital de Mataró, Barcelona, Spain; 28Service d’Epidémiologie et de Santé Publique, Hôpital de Bicêtre,
AP-HP; INSERM U1018; Université Paris-Sud, France; 29Research Department of Infection and Population Health, University College London, United
Kingdom; 30INSERM, CESP Centre for Research in Epidemiology and Population Health, Epidemiology of HIV and STI Team, Université Paris-Sud, Le
Kremlin Bicêtre, France; 31Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Switzerland; 32Department of Infectious
Diseases, St Pierre University Hospital, Brussels, Belgium; 33Division of Infectious Diseases, University of Alabama at Birmingham; 34Servicio de Medicina
Interna, Hospital de Sierrallana Torrelavega, Cantabria, Spain; 35Veterans Affairs Connecticut Healthcare System, West Haven; 36Department of Internal
Medicine, Yale University School of Medicine, New Haven, Connecticut; 37Division of Infectious Diseases, Vanderbilt University School of Medicine,
Nashville, Tennessee; 38Clinical Epidemiology and Health Services Research Core, Center for AIDS Research, University of Washington, Seattle; and
39School of Social and Community Medicine, University of Bristol, United Kingdom
Background. Some human immunodeﬁciency virus (HIV)–infected individuals initiating combination antire-
troviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to
identify (1) risk factors for failure to achieve CD4 count >200 cells/µL after 3 years of sustained viral suppression
and (2) the association of the achieved CD4 count with subsequent mortality.
Methods. We included treated HIV-infected adults from 2 large international HIV cohorts, who had viral sup-
pression (≤500 HIV type 1 RNA copies/mL) for >3 years with CD4 count ≤200 cells/µL at start of the suppressed
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period. Logistic regression was used to identify risk factors for incomplete CD4 recovery (≤200 cells/µL) and Cox regression to iden-
tify associations with mortality.
Results. Of 5550 eligible individuals, 835 (15%) did not reach a CD4 count >200 cells/µL after 3 years of suppression. Increasing
age, lower initial CD4 count, male heterosexual and injection drug use transmission, cART initiation after 1998, and longer time
from initiation of cART to start of the virally suppressed period were risk factors for not achieving a CD4 count >200 cells/µL. In-
dividuals with CD4 ≤200 cells/µL after 3 years of viral suppression had substantially increased mortality (adjusted hazard ratio, 2.60;
95% conﬁdence interval, 1.86–3.61) compared with those who achieved CD4 count >200 cells/µL. The increased mortality was seen
across different patient groups and for all causes of death.
Conclusions. Virally suppressed HIV-positive individuals on cART who do not achieve a CD4 count >200 cells/µL have sub-
stantially increased long-term mortality.
Keywords. HIV; CD4 cell recovery; sustained viral suppression; risk factors; mortality.
The introduction of combination antiretroviral therapy (cART)
has decreased morbidity and mortality in individuals infected
with human immunodeﬁciency virus (HIV) due to viral suppres-
sion and CD4 cell recovery [1–3].However, some individuals treat-
ed with cART achieve viral suppression but not CD4 cell recovery
[4–6]. Several studies have shown that individuals with successful
virological response to cART and incomplete CD4 recovery have
increased mortality [4, 5, 7–9]. However, the only previous study
exclusively examining long-term mortality in individuals started
late on cART with sustained viral load (VL) suppression and
low CD4 count is limited by small sample size [8].
By combining data from 2 large international collaborations of
HIV cohorts, the Antiretroviral Therapy Cohort Collaboration
(ART-CC) and the Collaboration of Observational HIV Epidemi-
ological Research Europe (COHERE), we examined risk factors
for failure to achieve CD4 recovery among treated individuals
whowere virally suppressed for >3 years, and comparedmortality
rates after 3 years of viral suppression according to the CD4 cell
count reached at the end of the virally suppressed period.
METHODS
Setting and Participants
The ART-CC (http://www.art-cohort-collaboration.org) is an in-
ternational collaboration of 18 cohort studies of HIV type 1
(HIV-1)–positive individuals from Europe and North America
that was established in 2000 to examine the prognosis of HIV-
1–positive, treatment-naive individuals initiating cART [10].CO-
HERE (http://www.cohere.org) was established in 2005 and is an
international collaboration of 35 cohorts from 29 European
countries. The COHERE data were pooled within the EuroCoord
network (www.eurocoord.net). Each collaboration focuses on sci-
entiﬁc questions requiring large sample sizes, which the contrib-
uting cohorts cannot answer individually [11].
Study Population and Design
We identiﬁed all HIV-1–positive individuals who (1) were >16
years old at start of the suppressed period; (2) were on cART con-
tinuously (deﬁned in ART-CC as treatment with at least 3 drugs
from 2 different classes and in COHERE as the concomitant use
of at least 3 antiretroviral drugs) for at least 3 years; (3) after start
of cART had a period with suppressed VL of at least 3 years (all
VL ≤500 HIV-1 RNA copies/mL and never a time span of >7
months between VL measurements); and (4) had a CD4 cell
count ≤200 cells/µL at the start of the virally suppressed period
(Figure 1). Individuals enrolled in >1 cohort were identiﬁed and
only 1 record per individual was included. A VL cutoff of ≤500
copies/mL was chosen to overcome the heterogeneity of the assay
detection limits used during the study period.
Statistical Analysis
Risk Factors for Failure to Achieve a CD4 Count >200 Cells/
µL After 3 Years of Viral Suppression
We used logistic regression to identify risk factors for not
achieving CD4 count >200 cells/µL after 3 years of sustained
viral suppression. We assessed the effect of CD4 cell count at
the start of the suppressed period as a categorical variable
(0–25, 26–50, 51–100, 101–150, and 151–200 cells/µL). In a
sensitivity analysis, we ﬁt separate models for each of these
CD4 strata. The following variables were included in all models:
age at start of virally suppressed period (<30, 30–39, 40–49, ≥50
years), probable route of infection (men who have sex with men
[MSM], male heterosexual sex, female heterosexual sex, injec-
tion drug use [IDU], other/unknown [the number of male
and female injection drug user and other/unknowns did not
allow for further classiﬁcation according to sex]), pre-cART
VL (last VL available within 3 months before start of cART
or ﬁrst VL within a month after start of cART if the former
was not available; VL <100 000 copies/mL, ≥100 000 copies/
mL, and missing), year of cART initiation (1996–1997, 1998–
2000, 2001 onward), time from cART initiation to start of sup-
pressed period (<12 months, ≥12 months), AIDS (no AIDS
event, ≥1 AIDS event before start of the virally suppressed pe-
riod). We tested for interactions between pairs of variables.
Risk Factors for Mortality After 3 Years of Viral Suppression
Person-years at risk were calculated from the date of the ﬁrst
CD4 count within 3 months after 3 years of viral suppression
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to the earlier of time of death, loss to follow-up, or end of ob-
servation. We estimated mortality rates and Kaplan-Meier plots
according to CD4 count at the end of the 3-year virally sup-
pressed period (≤200, 201–350, 351–500, or >500 cells/µL)
and used Cox regression to estimate hazard ratios (HRs) for
death according to these CD4 count groups. All analyses were
adjusted for the covariates listed above (AIDS events in this
analysis were up to the end of the virally suppressed period)
and stratiﬁed by cohort. We used Cox regression to compare in-
dividuals with CD4 counts ≤200 cells/µL and >200 cells/µL at
the end of the suppressed period within strata deﬁned by age
at start of virally suppressed period, route of infection, AIDS
status, and CD4 at start of suppressed period. In sensitivity anal-
yses, we used a cutoff value of 50 copies/mL to deﬁne viral sup-
pression and included only study subjects reporting sexual route
of transmission and no positive test for hepatitis C virus (HCV)
coinfection (HCV was deﬁned as a positive test for HCV RNA
or a positive test for HCV immunoglobulin G antibody at any
time during follow-up).
Analysis of Causes of Death
COHERE does not collect data on causes of death, so these
analyses were restricted to individuals included in ART-CC.
Supplementary Data 1 describes how the causes of death data
in this study were assigned and categorized. Causes of death
were further categorized as AIDS deﬁning, non–AIDS deﬁning,
unnatural (accident/violent/suicide/drug abuse), and unknown
[12]. Non-AIDS causes of death were further divided into hep-
atitis, cancers, and other. Because analyses of different causes of
death can pose the problem of competing risks, we estimated
both subdistribution HRs (using the Fine and Gray approach)
and standard (Cox) HRs (adjusted only for age and sex due
to the small number of events) [13]. Because these estimates
did not differ appreciably, we report only the estimates from
Cox models. SPSS statistical software, version 15.0 (Norusis;
SPSS Inc, Chicago, Illinois) and R software, version 2.8.1,
were used for data analysis.
RESULTS
We identiﬁed 113 845 unique HIV-1–positive individuals from
the COHERE and ART-CC cohorts, of whom 41 081 were treat-
ed with cART for <3 years, 50 495 did not have sustained viral
suppression, and 368 had no available CD4 measurement at the
start of the suppressed period. Of 21 901 individuals who
achieved sustained viral suppression for ≥3 years, 16 193 had
a CD4 count >200 cells/µL at start of the virally suppressed pe-
riod and 158 had no available CD4 measurement at the end of
the suppressed period, leaving 5550 individuals (20 291 person-
years of observation; median follow-up time; 3.4 years [inter-
quartile range, 1.6–5.3 years]) eligible for analyses (Figure 1).
A histogram of the distribution of CD4 count at the start of
the virally suppressed period is shown in Supplementary Data
2. The majority of these (4715 [85.0%]) achieved a CD4
count >200 cells/µL after 3 years of viral suppression. Half
(2904 [52.3%]) were aged >40 years at the start of the sup-
pressed period (Table 1).
Risk Factors for Failure to Achieve CD4 Count >200 Cells/µL
We found that risk of failure to achieve a CD4 count >200 cells/
µL increased with increasing age and with decreasing CD4
count at start of the virally suppressed period (Table 2).
Figure 1. Flowchart and study timeline. *Of the 41 081 patients who were
not on combination antiretroviral therapy for >3 years, 4677 (11.3%) died.
Among these individuals, 1020 (12.8%) had an available viral load measure-
ment within 3 months from date of death, and 44 (4.3%) were virally sup-
pressed at time of death. Abbreviations: ART-CC, Antiretroviral Therapy
Cohort Collaboration; cART, combination antiretroviral therapy; COHERE, Col-
laboration of Observational HIV Epidemiological Research Europe; HIV-1,
human immunodeﬁciency virus type 1; VL, viral load.
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Compared with MSM, men with heterosexual route of infec-
tion, injection drug users, and those with other or unknown
transmission group had greater risk of incomplete CD4
recovery. Risk was also greater in those whose last viral load be-
fore start of cART was <100 000 copies/mL, those who initiated
cART after 1998, and those who had 12 months or more from
initiation of cART to start of the virally suppressed period. In
models stratiﬁed on CD4 at start of the suppressed period,
the impact of age and AIDS-deﬁning illness on incomplete
CD4 recovery appeared to be similar across CD4 strata (Supple-
mentary Table 1). Patients infected via IDU had consistently
Table 2. Factors Associated With Failure to Achieve CD4 Count
>200 Cells/µL After 3 Years of Viral Suppression on Combination
Antiretroviral Therapy
Factor
Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
Age at start of the suppressed period, y
<30 1 (reference) 1 (reference)
30–39 1.36 (.97–1.89) 1.31 (.93–1.85)
40–49 2.17 (1.56–3.03) 2.04 (1.45–2.88)
≥50 3.98 (2.85–5.55) 4.01 (2.84–5.68)
Route of transmission
MSM 1 (reference) 1 (reference)
Male heterosexual sex 1.62 (1.32–1.98) 1.50 (1.21–1.85)
Female heterosexual sex 0.81 (.63–1.04) 0.89 (.68–1.15)
Injection drug use 1.96 (1.54–2.48) 2.03 (1.57–2.61)
Other/unknown 2.02 (1.62–2.52) 1.72 (1.37–2.17)
CD4 count at start of suppressed period, cells/µL
≤25 3.90 (2.86–5.32) 5.21 (3.75–7.23)
26–50 3.39 (2.58–4.44) 4.46 (3.35–5.95)
51–100 3.21 (2.59–3.97) 3.73 (2.99–4.68)
101–150 1.95 (1.57–2.42) 2.08 (1.67–2.60)
151–200 1 (reference) 1 (reference)
Last viral load measurement before start of cARTb, copies/mL
<100 000 1.07 (.92–1.24) 1.13 (.97–1.33)
≥100 000 1 (reference) 1 (reference)
Year of start of cART
1996–1997 1 (reference) 1 (reference)
1998–2000 1.28 (.97–1.69) 1.44 (1.07–1.93)
2001 onward 1.07 (.81–1.40) 1.37 (1.02–1.84)
Time from cART initiation to start of suppressed period, mo
<12 1 (reference) 1 (reference)
≥12 1.73 (1.45–2.06) 2.05 (1.68–2.50)
1 or more AIDS events before start of suppressed period
No AIDS event 1.17 (1.01–1.35) 0.89 (.76–1.04)
AIDS event 1 (reference) 1 (reference)
From the Antiretroviral Therapy Cohort Collaboration (ART-CC) and the
Collaboration of Observational HIV Epidemiological Research Europe
(COHERE), 2012.
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval;
HIV, human immunodeficiency virus; MSM, men who have sex with men; OR,
odds ratio.
a All variables are included in the adjusted estimates.
b One hundred thirty-six individuals had no baseline viral load andwere included
in the analysis as missing viral load.
Table 1. Clinical and Demographic Characteristics of 5550
Eligible HIV-Infected Individuals
Characteristic
CD4 Count at End of Virally
Suppressed Period
≤200 Cells/µL >200 Cells/µL
No. of patients (person-years
of observation)
835 (2936) 4715 (17 355)
No. of deaths (mortality rate per
100 person-years at risk)
66 (2.2) 109 (0.6)
Median time from start of cART to
start of the suppressed period,
mo (IQR)
2.8 (1.3–12.1) 2.5 (1.2–5.5)
Age at start of the suppressed period, y
<30 45 (5.4) 512 (10.9)
30–39 233 (27.9) 1956 (41.5)
40–49 275 (32.9) 1440 (30.5
>50 282 (33.8) 907 (17.1)
Route of transmission
MSM 227 (27.2) 1695 (35.9)
Male heterosexual sex 216 (25.9) 995 (21.1)
Female heterosexual sex 101 (12.1) 933 (19.8)
Injection drug use 128 (15.3) 489 (10.4)
Other/unknown 163 (18.6) 603 (12.8)
CD4 count at start of the suppressed period, cells/µL
≤25 75 (9.0) 223 (4.7)
26–50 108 (12.9) 370 (7.8)
51–100 268 (32.1) 970 (20.6)
101–150 231 (27.7) 1377 (29.2)
151–200 153 (18.3) 1775 (37.6)
Last viral load measurement before start of cART, copies/mL
<100 000 391 (46.8) 2129 (38.4)
≥100 000 424 (50.8) 2470 (44.5)
Viral load measurement missing 20 (2.4) 116 (2.5)
Year of start of cART
1996–1997 69 (8.3) 442 (9.4)
1998–2000 336 (40.2) 1686 (35.8)
2001 onward 430 (51.5) 2587 (54.9)
Time from cART initiation to start of suppressed period, mo
<12 626 (75.0) 3952 (83.8)
≥12 209 (25.0) 763 (16.2)
1 or more AIDS events before start of suppressed period
No AIDS event 425 (51.9) 2580 (54.7)
AIDS event 410 (49.1) 2135 (45.3)
From the Antiretroviral Therapy Cohort Collaboration (ART-CC) and the
Collaboration of Observational HIV Epidemiological Research Europe
(COHERE), 2012. Data are presented as No. (%) unless otherwise specified.
Abbreviations: cART, combination antiretroviral therapy; HIV, human
immunodeficiency virus; IQR, interquartile range; MSM, men who have sex
with men.
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higher risk of incomplete CD4 recovery than those infected via
MSM transmission.
Time to Death From Any Cause
A total of 175 (3.2%) individuals died: 66 (7.9%) of those who
did not attain a CD4 count >200 cells/µL and 109 (2.3%) of
those who attained a CD4 count >200 cells/µL. Table 3 shows
that individuals who did not attain a CD4 count >200 cells/
µL after 3 years of sustained viral suppression had substantially
increased mortality compared with those who achieved a CD4
count >200 cells/µL (adjusted HR, 2.60 [95% CI, 1.86–3.61]).
The cumulative probability of survival stratiﬁed by CD4 count
is presented in Figure 2. The estimated 5-year cumulative mor-
tality (with 95% CIs) was 11.8% (8.9%–15.2%) in patients with a
CD4 count <200 cells/µL at the end of the suppressed period,
compared with 4.1% (3.1%–5.3%), 2.2% (1.4%–3.4%), and
2.2% (1.2%–3.7%) in patients with a CD4 count of 201–350,
351–500, and >500 cells/µL, respectively, at the end of the
suppressed period. Compared with individuals with CD4
count >500 cells/µL at the end of the suppressed period,
adjusted HRs in individuals with a CD4 count of 351–500,
201–350, and ≤200 CD4 cells/µL were 0.62 (95% CI, .32–
1.19), 1.28 (95% CI, .74–2.23), and 2.62 (95% CI, 1.47–4.67),
respectively.
Table 3. Mortality Hazard Ratios Comparing Individuals With CD4 Count ≤200 and >200 Cells/µL at the End of the Suppressed Period
Strata
Deaths, No. Person-Years of Observation
Crude HR(95% CI)
Adjusteda
HR (95% CI)≤200 Cells/µL >200 Cells/µL ≤200 Cells/µL >200 Cells/µL
All individuals 66 109 2937 17 346 3.35 (2.46–4.57) 2.60 (1.86–3.61)
Age, y
<30 1 2 154 1826 NA NA
30–39 8 25 863 7457 3.00 (1.33–6.76) 3.01 (1.26–7.16)
40–49 19 40 937 5174 2.50 (1.44–4.34) 2.04 (1.12–3.70)
≥50 38 42 983 2889 2.51 (1.61–3.93) 3.18 (1.96–5.14)
Route of transmission
MSM 13 30 84 6694 3.58 (1.85–6.93) 2.62 (1.28–5.34)
Male heterosexual 14 25 729 3516 2.86 (1.47–5.57) 2.41 (1.19–4.86)
Female heterosexual 7 7 298 2975 8.21 (2.80–24.05) NA
Injection drug use 12 27 461 1810 1.60 (.78–3.27) 1.43 (.65–3.17)
Other/unknown 20 20 605 2350 3.13 (1.68–5.83) 2.53 (1.26–5.07)
CD4 count at start of suppressed period, cells/µL
≤25 6 2 317 904 NA NA
26–50 6 5 452 1386 2.92 (.86–9.93) 2.76 (.66–11.46)
51–100 17 26 973 3731 2.56 (1.35–4.85) 1.43 (.71–2.88)
101–150 22 40 735 5022 3.40 (2.00–5.75) 2.62 (1.49–4.60)
151–200 15 36 459 6303 5.57 (3.01–10.32) 3.82 (1.95–7.45)
Last viral load before start of cART, copies/mL
Viral load <100 000 30 51 1365 7520 2.98 (1.88–4.72) 2.23 (1.34–3.72)
Viral load ≥100 000 33 58 1517 9504 3.19 (2.06–4.94) 2.61 (1.63–4.18)
Year of cART initiation
1996–1997 8 22 394 2750 2.87 (1.24–6.64) 2.25 (.87–5.84)
1998–2000 40 56 1535 8453 3.65 (2.42–5.51) 2.74 (1.74–4.30)
2001 onward 18 31 1008 6143 3.39 (1.87–6.14) 3.03 (1.62–5.65)
Time from cART initiation to start of suppressed period, mo
<12 18 18 573 2336 3.04 (2.13–4.33) 2.51 (1.23–5.14)
≥12 48 91 2363 15 010 3.96 (2.03–7.70) 2.53 (1.72–3.70)
1 or more AIDS events by end of suppressed period
No AIDS event 28 48 13 507 8584 3.51 (2.18–5.64) 2.49 (1.47–4.20)
AIDS event 38 61 1587 8762 3.05 (2.02–4.61) 2.47 (1.59–3.83)
From the Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), 2012.
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; MSM, men who have sex
with men; NA, numbers in these strata were too small for an analysis to be performed.
a Adjusted for all other covariates listed in the table. Stratification factor removed from list of adjustments.
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Mortality Hazard Ratios Stratiﬁed by Risk Factors
Table 3 shows that the impact on mortality of not achieving a
CD4 count >200 cells/µL was most pronounced in individuals
whose CD4 count at the start of the suppressed period was
151–200 cells/µL (those in whom the increase in CD4 since
start of ART was lowest). However, estimated HRs within
CD4 strata were estimated imprecisely, and their CIs over-
lapped. The impact of incomplete CD4 recovery appeared sim-
ilar across strata deﬁned by age, mode of transmission, viral load
before start of cART, year of cART initiation, time from initia-
tion of cART to start of the virally suppressed period, and
AIDS-deﬁning disease (Table 3).
Sensitivity Analyses
Of 2692 individuals who were eligible when a cutoff of 50 cop-
ies/mL for viral suppression was used, 2253 (83.7%) achieved a
CD4 count >200 cells/µL. Estimated effects of risk factors for
not achieving a CD4 count >200 cells/µL were broadly similar
to those in the main analyses, although there was less evidence
of elevated risk among heterosexual men (adjusted odds ratio,
1.17 [95% CI, .88–1.55]) and women (0.64 [95% CI, .45–.93])
(Supplementary Table 2). In this analysis, a total of 33 (7.5%)
and 41 (1.8%) individuals with and without incomplete CD4
recovery, respectively, died during follow-up, and the adjusted
HR for not attaining (compared with attaining) a CD4 count
>200 cells/µL was 3.96 (95% CI, 2.36–6.66). Exclusion of 1625
(29.3%) individuals who did not report sexual route of transmis-
sion nor had HCV coinfection left 3925 individuals with 87
deaths. The adjusted HR for not attaining (compared with attain-
ing) a CD4 count >200 cells/µL was 2.98 (95% CI, 1.85–4.79).
Time to Death From Speciﬁc Causes
Of 4135 individuals included in analyses of cause-speciﬁc mortal-
ity, 619 (15.0%) did not attain a CD4 count >200 cells/µL after
the suppressed period and 121 (2.9%) died. Most deaths were
from non-AIDS-deﬁning causes, in both groups (Table 4). Mor-
tality due to AIDS-deﬁning, non-AIDS-deﬁning, and unnatural
causes of death was increased substantially in individuals who
did not attain a CD4 count >200 cells/µL and was highest for
hepatitis and non-AIDS-deﬁning cancers (adjusted HRs, 6.76
[95% CI, 1.93–23.74] and 2.89 [95% CI, 1.44–5.28], respectively).
DISCUSSION
Based on data combined from 2 large international HIV cohort
collaborations, we found that among HIV-positive individuals
with 3 years of viral suppression on cART, those with incom-
plete CD4 recovery (CD4 count ≤200 cells/µL) had markedly
higher mortality rates than those who achieved a CD4 count
>200 cells/µL. These higher rates were observed consistently
across strata deﬁned by age, sex, route of transmission, and
prior AIDS-deﬁning illness. Rates of both AIDS- and non-
AIDS-deﬁning causes of death were elevated. We identiﬁed
older age, transmission via male heterosexual sex or IDU,
lower CD4 count at start of the suppressed period, and longer
time from initiation of cART to start of the virally suppressed
period as risk factors for incomplete CD4 cell recovery.
Strengths and Weaknesses
Because 15% of treated HIV-positive individuals have a CD4
count <200 cells/µL after long-term viral suppression, prognosis
of such patients is a major concern. By combining data from
2 collaborations of HIV cohort studies, we assembled a sufﬁ-
ciently large data set to permit us to examine both risk factors
and prognosis for all-cause and cause-speciﬁc mortality among
patients with incomplete CD4 recovery. The contributing co-
hort studies represent a wide variety of countries and settings,
and our results are therefore likely to be generalizable to treated
HIV-positive individuals in Western Europe and North Amer-
ica. Not all contributing cohorts link their data with national
death registries, which may lead to an underestimation of mor-
tality rates. However, estimates of relative mortality comparing
different groups should not be biased, providing that nonascer-
tained deaths are missing at random [14]. Serological tests for
coinfection with HCV were not performed systematically
in all cohorts; therefore, some coinfected individuals may
have been misclassiﬁed. However, ﬁndings were similar in a
Figure 2. Cumulative probability of survival stratiﬁed by CD4 count at the
end of the virally suppressed period: ≤200 cells/µL (full line); 201–350
cells/µL (broken line); 351–500 cells/µL (dotted line); and >500 cells/µL
(broken and dotted line).
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sensitivity analysis excluding both injection drug users and
HCV-coinfected individuals, and the impact of misclassiﬁca-
tion of HCV serostatus may have been limited because of its
strong association with transmission via IDU, which was avail-
able from all cohorts. We did not have access to data on smok-
ing, other comorbidity (eg, diagnosis of non-AIDS cancers) or
non-cART medications (eg, cancer chemotherapy) and were
therefore not able to adjust for such factors or assess whether
they predict incomplete CD4 recovery.
Our deﬁnition of CD4 recovery (CD4 count >200 cells/µL
after 3 years of viral suppression following cART initiation) dif-
fers from other deﬁnitions of recovery: for example, National
Institutes of Health guidelines deﬁned an adequate response
as an increase in CD4 count in the range of 50–150 cells/µL
per year [15]. Our deﬁnition of CD4 recovery was based on 2
considerations. First, the increase in CD4 count over time
since start of cART in virologically suppressed patients depends
on baseline CD4 count [6]. Second, the risk of mortality is
strongly related to current CD4 count [16, 17].
Results in Context With Other Literature
Previous studies have identiﬁed age [8, 18, 19] and low baseline
CD4 counts [4, 18, 20] as risk factors for incomplete CD4 cell
recovery. However, 2 of these [16, 20] used designs that differed
from ours in terms of inclusion criteria and length of the virally
suppressed period. The effect of age observed in our study is
consistent with its association with thymus size and activity
and suggests that initiation of cART before immune incompe-
tence occurs is especially important in older HIV-infected indi-
viduals [21–23].
Most studies that examined clinical endpoints according to
achieved CD4 count in virally suppressed patients used short
periods of viral suppression or did not have inclusion criteria
relating to baseline CD4 count [9, 17, 24]. These studies mainly
estimated short-term effects of changes in CD4 count, rather
than elucidating the long-term impact of sustained low CD4
cell counts in patients who are virally suppressed long-term.
Two previous studies examined implications of incomplete
CD4 recovery among patients with sustained viral suppression,
and our ﬁndings are in accordance with their estimates. Loutfy
et al observed a 2.69-fold (95% CI, 1.26- to 5.78-fold) increase
in mortality comparing 176 patients with a CD4 count <200
cells/µL with 1545 patients with a CD4 count >200 cells/µL
after 2 years of viral suppression [24]. That study had both a
shorter duration of and less strict criteria for viral suppression
as well as a much smaller and less generalizable sample. We
previously reported the relative risk of death to be 3.4 (95% CI,
1.4–8.0) in a small study comparing 55 immunological non-
responders with 236 responders in the Danish HIV Cohort
Study, using a design almost identical to that of the present
study [8]. Data on causes of death were not available in either of
these 2 studies. Although we observed increased mortality in all
subgroups of individuals with poor CD4 recovery, the relative
risk of death was greatest among individuals with baseline CD4
count between 151 and 200 cells/µL. These individuals are charac-
terized by the lowest increase (or even a decrease) in CD4 counts
during the 3-year period of virological suppression, a phenome-
non that may be related to non-HIV comorbidity such as cancer.
Consistent with our results, previous studies have found in-
complete CD4 recovery to be associated with an increased risk
Table 4. Cause-Speciﬁc Hazard Ratios Comparing HIV-Infected Individuals (ART-CC Only) With CD4 Count ≤200 Versus >200 Cells/µL at
End of Suppressed Period
Causes of Death
No. (%) of Deaths According to CD4
Count at End of Suppressed Period HR (95% CI)
≤200 Cells/µL >200 Cells/µL Unadjusted Adjusteda
All 41 (100) 80 (100) 3.05 (2.10–4.44) 2.52 (1.71–3.70)
AIDS-defining causes of death 4 (9.8) 7 (8.8) 3.39 (0.99–11.57) 2.75 (0.78–9.69)
Non-AIDS-defining causes of death 26 (63.4) 49 (61.3) 3.14 (1.95–5.06) 2.61 (1.61–4.23)
Hepatitis 5 5 5.95 (1.72–20.56) 6.76 (1.93–23.74)
Non-AIDS cancer 14 23 3.50 (1.73–6.95) 2.89 (1.44–5.28)
Other causes of deathb 6 21 1.69 (0.68–4.18) 1.24 (0.50–3.12)
Unnatural causes of death 3 (7.3) 8 (10.0) 2.27 (0.60–8.57) 2.07 (0.54–7.97)
Unknown causes of death 8 (19.5) 16 (19.5) 3.00 (1.28–7.01) 2.34 (0.98–5.59)
From the Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), 2012.
Abbreviations: ART-CC, Antiretroviral Therapy Cohort Collaboration; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio.
aAdjusted for sex and age (≤50 years vs >50 years).
bOther causes of death for patients with CD4 count ≤200 cells/µL were related to infection (2), cardiovascular disease (2), and digestive system disease (2). Other
causes of death for patients with CD4 count >200 cells/µL were related to infection (5), lung diseases (2), cardiovascular diseases (9), digestive system diseases (2),
central nervous system diseases (2), and renal diseases (1).
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of non-AIDS cancer [25–27]. It is still a matter of debate wheth-
er low CD4 counts lead to non-AIDS-deﬁning cancers or
whether common risk factors lead to low CD4 count and
non-AIDS-deﬁning cancers. Higher rates of non-AIDS mortal-
ity among individuals with incomplete CD4 recovery may be re-
lated to chronic immune activation in virally suppressed
individuals [28, 29].
Implications and Conclusions
Our data underline the importance of early diagnosis of HIV
and treatment with cART before patients have a low CD4
count. Although we have identiﬁed risk factors for poor CD4
recovery, no interventions to increase CD4 count in virally sup-
pressed patients have been demonstrated to have beneﬁcial ef-
fects on clinical endpoints and mortality. Previous studies have
not consistently demonstrated differences between antiretrovi-
ral drug classes in effects on CD4 increases, and attempts to in-
crease CD4 count with interleukin 2 were futile in terms of
clinical beneﬁt [30–32]. Virally suppressed patients with low
CD4 counts should be monitored closely for diseases not con-
ventionally considered to be HIV related, especially non-AIDS-
deﬁning cancers and liver diseases. Our study demonstrated an
increased risk of non-AIDS causes of death in immunological
nonresponders; further research is needed to elucidate the
mechanisms that lead to persistently low CD4 counts despite
viral suppression.
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